The present invention comprises a purposefully formulated weight loss composition and a method for causing a meaningful weight loss in a living human subject. The formulated weight loss composition, in its most preferred embodiments comprises: at least one amino acid that is a pharmacologically active precursor in the catecholamine biosynthesis pathway; one or more sympathomimetic agents; a lipolytic agent; a high-Dalton macromolecular protein, and a plurality of micronutrients. The preferred composition is formulated as a dry particulate admixture initially; and then is made into a fluid beverage, which is able to achieve multiple physiologic functions in-vivo. These in-vivo functions include: causing a meaningful weight loss, with a preference for lipolysis and fat metabolism; providing for a low glycemic index; offering lean muscle maintenance and replenishment; and concomitantly initiating dopaminergic (D2-receptor) brain stimulation, resulting in improved cognitive function and affective augmentation.